Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma

Tumors with high mutation load are thought to engender stronger immune responses, which in turn promote prolonged patient survival. To investigate this, we assessed tumor-infiltrating lymphocytes (TILs) and immunosuppressive factors across the 4 molecular subtypes of endometrial cancer, which have c...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical cancer research Ročník 25; číslo 8; s. 2537
Hlavní autori: Talhouk, Aline, Derocher, Heather, Schmidt, Pascal, Leung, Samuel, Milne, Katy, Gilks, C Blake, Anglesio, Michael S, Nelson, Brad H, McAlpine, Jessica N
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 15.04.2019
Predmet:
Endometrial Neoplasms - genetics
Female
Humans
Immunotherapy
Lymphocytes, Tumor-Infiltrating - immunology
Mutation
Prognosis
ISSN:1078-0432, 1557-3265, 1557-3265
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Tumors with high mutation load are thought to engender stronger immune responses, which in turn promote prolonged patient survival. To investigate this, we assessed tumor-infiltrating lymphocytes (TILs) and immunosuppressive factors across the 4 molecular subtypes of endometrial cancer, which have characteristic mutation rates ranging from low to ultra-high. A total of 460 endometrial cancers were stratified by ProMisE (Proactive Molecular Risk Classifier in Endometrial cancer) into 4 molecular subtypes: mismatch repair-deficient (MMRd), mutant (POLE), p53 abnormal (p53abn), and p53 wild-type (p53wt). Immune markers (CD3, CD8, CD79a, CD138, PD-1, PD-L1, FoxP3, IDO-1) were quantified by multiplex IHC and tested for associations with ProMisE subtype, survival, and other clinicopathologic parameters. Two major TIL patterns were observed. TIL tumors harbored dense T- and B-lineage infiltrates and multiple immunosuppressive features and were common in molecular subtypes associated with high mutation load (MMRd and POLE); however, equally strong responses were seen in significant numbers of p53abn and p53wt tumors, which have characteristically low mutation loads. TIL tumors were generally devoid of immunologic features and were more prevalent in p53abn and p53wt endometrial cancers, yet were also seen in MMRd and POLE subtypes. In multivariable models involving ProMisE subtype, T-cell markers, and TIL clusters, only ProMisE showed independent prognostic significance. Immune response correlates with endometrial cancer molecular subtype but does not carry independent prognostic significance. Profound variation in immune response is seen across and within endometrial cancer molecular subtypes, suggesting that assessment of immune response rather than molecular subtype may better predict response to immunotherapy. .
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1078-0432
1557-3265
1557-3265
DOI:10.1158/1078-0432.CCR-18-3241